ALUMINUM PLASMA OR SERUM
General Information
HLAB/HOL Code: ALU
UPHSM LIS Test #: 027130
Schedule:
Testing Time: 2-4 days
Testing Lab: Labcorp
UPHSM LIS Test #: 027130
Schedule:
Testing Time: 2-4 days
Testing Lab: Labcorp
Specimen Info
Only 1 specimen type required, unless otherwise specified
Volume: 7 mL (0.6 min)
Temperature: Ambient
Tube Type: serum or plasma
Collection Info:
Container: Royal blue-top (EDTA) tube or royal blue-top without EDTA
Separate serum or plasma immediately after the collection, and transfer to a certified metal-free transport tube for shipment to the laboratory.
Temperature: Ambient
Tube Type: serum or plasma
Collection Info:
Container: Royal blue-top (EDTA) tube or royal blue-top without EDTA
Separate serum or plasma immediately after the collection, and transfer to a certified metal-free transport tube for shipment to the laboratory.
Specimen Acceptability
Causes for Rejection:
Royal blue-top tube not used in specimen collection; certified metal-free plastic transport tube not submitted
Royal blue-top tube not used in specimen collection; certified metal-free plastic transport tube not submitted
Methods
Inductively coupled plasma/mass spectrometry (ICP/MS)
Clinical Utilities
Monitor patients for prior and ongoing exposure to aluminum. Patients at risk include:
• Infants on parenteral fluids, particularly parenteral nutrition
• Burn patients through administration of intravenous albumin, particularly with coexisting renal failure
• Adult and pediatric patients with chronic renal failure who accumulate aluminum readily from medications and dialysate
• Adult parenteral nutrition patients (less so, recently)
• Patients with industrial exposure
Monitor dialysate and water to prepare dialysate to prevent aluminum toxicity in dialysis patients.
Limitations: Serum levels rise and fall after each dose of aluminum-containing phosphate binder or sucralfate. If renal function is normal, renal clearance of aluminum is prompt, with urine levels rising quickly after a course of aluminum-containing antacid is begun, and with levels persisting elevated for over a week. Urine levels rise after a dose of deferoxamine given for any reason. The degree of rise in serum aluminum after deferoxamine is regarded as reflecting total body aluminum burden.
• Infants on parenteral fluids, particularly parenteral nutrition
• Burn patients through administration of intravenous albumin, particularly with coexisting renal failure
• Adult and pediatric patients with chronic renal failure who accumulate aluminum readily from medications and dialysate
• Adult parenteral nutrition patients (less so, recently)
• Patients with industrial exposure
Monitor dialysate and water to prepare dialysate to prevent aluminum toxicity in dialysis patients.
Limitations: Serum levels rise and fall after each dose of aluminum-containing phosphate binder or sucralfate. If renal function is normal, renal clearance of aluminum is prompt, with urine levels rising quickly after a course of aluminum-containing antacid is begun, and with levels persisting elevated for over a week. Urine levels rise after a dose of deferoxamine given for any reason. The degree of rise in serum aluminum after deferoxamine is regarded as reflecting total body aluminum burden.
CPT Codes
82108
* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Reference Range
Reference Interval:
Environmental exposure: 0-9 μg/L
patients on dialysis: <40 μg/L
Critical Values: Potentially toxic: >60 μg/L
Environmental exposure: 0-9 μg/L
patients on dialysis: <40 μg/L
Critical Values: Potentially toxic: >60 μg/L
